Literature DB >> 13784890

Vincaleukoblastine in the treatment of malignant disease.

D M WHITELAW, J M TEASDALE.   

Abstract

Entities:  

Keywords:  ALKALOIDS/therapy; ANTINEOPLASTIC AGENTS/therapy

Mesh:

Substances:

Year:  1961        PMID: 13784890      PMCID: PMC1848533     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Colonic urinary conduits.

Authors:  R T WARWICK
Journal:  Proc R Soc Med       Date:  1960-12

2.  Effect of Vincaleukoblastine on metastatic choriocarcinoma and related trophoblastic tumors in women.

Authors:  R HERTZ; M B LIPSETT; R H MOY
Journal:  Cancer Res       Date:  1960-08       Impact factor: 12.701

3.  Role of chance observations in chemotherapy: Vinca rosea.

Authors:  R L NOBLE; C T BEER; J H CUTTS
Journal:  Ann N Y Acad Sci       Date:  1958-12-05       Impact factor: 5.691

4.  Vincaleukoblastine. I. Preliminary clinical studies.

Authors:  M E HODES; R J ROHN; W H BOND
Journal:  Cancer Res       Date:  1960-08       Impact factor: 12.701

5.  Acute leukaemia in adults treated with 6-mercaptopurine.

Authors:  D M WHITELAW; R G MOFFAT; W H PERRY; R E BECK
Journal:  Can Med Assoc J       Date:  1956-03-15       Impact factor: 8.262

  5 in total
  5 in total

1.  Chemotherapy of malignant disease: a review of theory and practice.

Authors:  G D HART
Journal:  Can Med Assoc J       Date:  1962-03-31       Impact factor: 8.262

2.  [Long term treatment of advanced lymphogranulomatosis with vinblastine sulfate].

Authors:  E Schulz; W Jüngling; K Hausmann
Journal:  Klin Wochenschr       Date:  1969-02-15

3.  VINCRISTINE IN THE TREATMENT OF NEOPLASTIC DISEASE.

Authors:  D M WHITELAW; H S KIM
Journal:  Can Med Assoc J       Date:  1964-06-20       Impact factor: 8.262

4.  Clinical experience with vincaleukoblastine sulfate in the treatment of 11 patients with Hodgkin's disease.

Authors:  K R Butler
Journal:  Can Med Assoc J       Date:  1965-10-02       Impact factor: 8.262

5.  A comparison of nitrogen mustard and vinblastine sulfate in the treatment of patients with Hodgkin's disease.

Authors:  R E Alison; D M Whitelaw
Journal:  Can Med Assoc J       Date:  1970-02-14       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.